<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01685814</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XIV</org_study_id>
    <secondary_id>2009-016616-21</secondary_id>
    <nct_id>NCT01685814</nct_id>
  </id_info>
  <brief_title>Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance</brief_title>
  <official_title>Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone (RAD)&#xD;
      as comparator arm for Lenalidomide, Bortezomib, Dexamethasone (VRD) with the latter being&#xD;
      considered a novel &quot;standard&quot; as an induction protocol, since response in general occurs&#xD;
      early after starting treatment we decided to choose three cycles of either induction regimen.&#xD;
&#xD;
      Together with the &quot;novel compounds&quot;, tandem high-dose melphalan is still the standard of&#xD;
      care; it seems desirable to re-address the question of the number of transplant (single vs.&#xD;
      double high-dose melphalan) procedures required in the context of triplet-induction protocols&#xD;
      utilizing at least one of the novel compounds.&#xD;
&#xD;
      Thus, the question to be asked in the current protocol is whether immediate lenalidomide&#xD;
      maintenance (i.e. following one cycle of high-dose therapy) as an investigational agent will&#xD;
      result in identical progression free survival (PFS) when compared to tandem high-dose&#xD;
      melphalan with deferred maintenance therapy.&#xD;
&#xD;
      Despite induction with novel compounds, approximately 25 - 40% of patients will be in less&#xD;
      than very good partial response. Very recently, achievement of less than VGPR was confirmed&#xD;
      to negatively impact on both PFS as well as overall survival (OS). Therefore, allogeneic stem&#xD;
      cell transplantation is considered the standard of care in patients with suboptimal response&#xD;
      to a first autograft.&#xD;
&#xD;
      In the current protocol, the standard for favourable responders (tandem-autologous&#xD;
      transplant) is combined with 3 years of lenalidomide maintenance. This approach will be&#xD;
      investigated for patients with less than VGPR following a first autotransplant and compared&#xD;
      to the current standard of intensification in poor responders (allogeneic transplantation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint for the induction phase is the rate of patients with CR at first restaging</measure>
    <time_frame>within 8 days after end of last induction cycle ((Day 92(RAD); Day 71(VRD))</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In the consolidation phase the primary efficacy endpoint for comparison II (response &lt;VGPR after first ASCT) is the PFS rate</measure>
    <time_frame>3 years after the first ASCT, calculated from day 1 of ASCT.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR following 3 cycles of induction treatment (VRD vs RAD)</measure>
    <time_frame>within 8 days after end of last induction cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR and ORR at the end of the whole treatment programme</measure>
    <time_frame>at the end of the whole treatment programme (approx. 8 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>8 years from study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, severity and relationship of SAEs</measure>
    <time_frame>30 days post last dosing of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of hospital stays and hospitalization days</measure>
    <time_frame>within two years from second restaging</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Previously Untreated Symptomatic Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tandem autologous transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Bortezomib</intervention_name>
    <description>Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy</description>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant</arm_group_label>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous stem cell transplant</intervention_name>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
    <arm_group_label>single stem cell transplant, 3-year lenalidomide maintenance</arm_group_label>
    <arm_group_label>tandem autologous transplant</arm_group_label>
    <arm_group_label>tandem autologous transplant, lenalidomide maintenance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic stem cell transplant</intervention_name>
    <arm_group_label>allogeneic stem cell transplant, lenalidomide maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  Patients willing and able to undergo autologous and allogeneic transplantation&#xD;
&#xD;
          -  no previous systemic therapy for the treatment of multiple myeloma (dexamethasone at a&#xD;
             cumulative dose of 320 mg; plasmapheresis/dialysis without concomitant chemotherapy,&#xD;
             local irradiation of bone lesions; and surgical intervention is accepted as&#xD;
             pretreatment)&#xD;
&#xD;
          -  Newly diagnosed multiple myeloma according to common diagnostic criteria including&#xD;
             presence of CRAB and measurable disease parameters&#xD;
&#xD;
          -  Cardiac ejection fraction (LVEF) of at least 50%&#xD;
&#xD;
          -  Corrected DLCO of at least 50% ; alternatively pO2 [art.] of at least 70mmHg&#xD;
&#xD;
          -  Karnofsky performance status of greater or equal to 50%&#xD;
&#xD;
          -  adequate bone marrow function&#xD;
&#xD;
          -  adequate serum chemistry values&#xD;
&#xD;
          -  Use of adequate contraception for female subjects with childbearing potential and male&#xD;
             subjects&#xD;
&#xD;
          -  Bone marrow sample available for analysis of molecular cytogenetics&#xD;
&#xD;
          -  Able to administer low molecular-weight heparin as a prophylactic anticoagulation&#xD;
             therapy for the first three months(applicable for subjects randomized to RAD) and able&#xD;
             to administer ASS 100 mg/d (applicable for subjects randomized to VRD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk&#xD;
&#xD;
          -  History of myocardial infarction; NYHA Class III or IV heart failure, uncontrolled&#xD;
             angina, severe uncontrolled ventricular arrhythmias; concomitant pericarditis or&#xD;
             peri-/myocarditis&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 28 days of baseline&#xD;
&#xD;
          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14&#xD;
             days before enrollment&#xD;
&#xD;
          -  Known intolerance of boron&#xD;
&#xD;
          -  Hypersensitivity to acyclovir or similar anti-viral drug&#xD;
&#xD;
          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical, breast or prostate cancer&#xD;
&#xD;
          -  HIV positive, active hepatitis B, C or D viral infection, known CMV&#xD;
             reactivation/active infection, EBV reactivation/active infection or treponema pallidum&#xD;
             infection&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Non-secretory MM&#xD;
&#xD;
          -  Clinically relevant active infection or serious co-morbid medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Knop, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hermann Einsele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Med. Klinik IV, Hämatologie u. Onkologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schön Klinik Starnberger See, Hämatologie und Onkologie</name>
      <address>
        <city>Berg</city>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Hämatologie, Onkologie u. Tumorimmunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Klinik für Innere Medizin I</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Woflgang Goethe Universität, Frankfurt am Mai</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH Medizinische Klinik I</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Abteilung für Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital gem. GmbHKna</name>
      <address>
        <city>Hamm</city>
        <zip>59071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes Innere Medizin I</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe Medizinische Klinik III, Abt. Hämatologie u. Onkologie</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Medizinische Klinik und Poliklinik II im städtischen Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein GmbH, Klinik für Innere Medizin</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim medizinische Klinik III</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Medizinische Klinik u. Poliklinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord, 5. Medizinische LKinik, Onkologie/Hämatologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH, Klinik für Innere Medizin II</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Regensburg, Abteilung für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Abt. Hämatologie, Onkologie u. Palliativmedizin</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm,Klinik für Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Kliniken, Klinik Innere Medizin III</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Wuerzburg, Medizinische Klinik II</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>September 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2012</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

